IGLV1-44 Gene: Structure, Function, and Clinical Significance

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-01

Key Takeaways

• The IGLV1-44 gene encodes a variable domain of the immunoglobulin lambda light chain, crucial for antigen binding via its three complementarity-determining regions (CDRs). Its V(D)J recombination and somatic hypermutation processes contribute to antibody diversity and affinity maturation, but aberrant mutations are implicated in B-cell malignancies like CLL and multiple myeloma.
• IGLV1-44 plays a significant role in autoimmune diseases, notably rheumatoid arthritis and systemic lupus erythematosus, where antibodies utilizing this gene can target self-antigens such as citrullinated proteins and dsDNA. Germline polymorphisms, like the K45E variant, are associated with increased CLL risk and differential response to therapies like rituximab.
• The gene is a critical biomarker for minimal residual disease (MRD) monitoring in B-cell malignancies, detectable through highly sensitive methods such as allele-specific oligonucleotide PCR (ASO-PCR) and next-generation sequencing (NGS), enabling precise quantification of clonal burden.
• Viral pathogens like EBV and HIV interact with IGLV1-44-expressing B cells; EBV's LMP2A mimics BCR signaling, promoting B-cell survival, while HIV gp120 can bind to IGLV1-44 CDR3, influencing antibody neutralization and therapeutic strategies for HIV.
• While not a direct drug target, IGLV1-44 is indirectly targeted by B-cell depleting therapies such as rituximab and daratumumab, and by CAR-T cell therapies (e.g., anti-CD19, anti-BCMA) used in treating B-cell malignancies. Small molecules like ibrutinib and venetoclax modulate BCR signaling pathways critical for these malignant cells.

Executive Summary & Key Metadata

The IGLV1-44 gene (Immunoglobulin Lambda Variable 1-44) encodes a variable domain of the immunoglobulin lambda light chain, a fundamental component of the adaptive immune system. This gene is a member of the immunoglobulin lambda variable (IGLV) gene family located on chromosome 22q11.2. The protein product, when rearranged with a lambda joining (IGLJ) segment and constant (IGLC) region, forms the light chain of antibodies that recognize and neutralize antigens. Beyond its canonical role in humoral immunity, IGLV1-44 has emerged as a clinically significant locus due to its involvement in B-cell malignancies, autoimmune disorders, and its utility as a biomarker for minimal residual disease (MRD) monitoring.

The IGLV1-44 gene product is a 112-amino-acid variable domain that folds into a characteristic immunoglobulin beta-sandwich structure. This domain contains three complementarity-determining regions (CDRs) that confer antigen specificity. The gene undergoes V(D)J recombination, somatic hypermutation (SHM), and class switch recombination (CSR) during B-cell development, making it a dynamic locus with significant genomic plasticity.

1. Genomic Locus, Chromosomal Organization & Isoforms

1.1 Chromosomal Location and Gene Structure

The IGLV1-44 gene is located on the long arm of chromosome 22 at band q11.2 (chr22:22,380,000–22,390,000; GRCh38/hg38). This region contains the entire immunoglobulin lambda light chain locus, which spans approximately 1.0 Mb and comprises:

• ~70 variable (V) genes (of which ~30 are functional)
• 7 joining (J) segments
• 7 constant (C) region genes (IGLC1–IGLC7)

The IGLV1-44 gene is positioned in the proximal cluster of the lambda variable region, approximately 200 kb upstream of the J-C cluster. The gene spans ~1.2 kb from the promoter to the recombination signal sequence (RSS) and contains:

• Exon 1 (leader sequence): Encodes a 15-amino-acid signal peptide that directs the nascent polypeptide into the endoplasmic reticulum.
• Intron 1: ~300 bp intervening sequence.
• Exon 2 (variable domain): Encodes the 112-amino-acid mature variable region, including framework regions (FR1–FR4) and CDRs.

The gene is flanked by a 5' promoter region containing a TATA box and octamer motif (ATTTGCAT), which is recognized by the B-cell-specific transcription factor OCT-2 (POU2F2) and the ubiquitous factor OCT-1 (POU2F1). A 3' recombination signal sequence (RSS) consisting of a heptamer (CACAGTG), a 23-bp spacer, and a nonamer (ACAAAAACC) directs V-J recombination.

1.2 Promoter Architecture and Enhancer Elements

The IGLV1-44 promoter is a class III RNA polymerase II promoter with the following architecture:

The lambda enhancer (Eλ) is located downstream of the IGLC genes and contains binding sites for PU.1, IRF4, and E2A. This enhancer is essential for high-level transcription in plasma cells. Additionally, a 3' enhancer (3'Eλ) located 40 kb downstream of IGLC1 has been shown to regulate class switch recombination and somatic hypermutation.

1.3 V(D)J Recombination and Isoform Diversity

The IGLV1-44 gene does not produce multiple splice isoforms in the conventional sense. Instead, its diversity arises from V(D)J recombination:

1. Rearrangement: The IGLV1-44 gene rearranges with one of the 7 IGLJ segments and one of the 7 IGLC segments.
2. Junctional diversity: Exonucleolytic trimming and terminal deoxynucleotidyl transferase (TdT)-mediated N-nucleotide addition at the V-J junction generate CDR3 diversity.
3. Somatic hypermutation: Activation-induced cytidine deaminase (AID) introduces point mutations in the rearranged V gene at a rate of ~10⁻³ per base pair per cell division, leading to affinity maturation.

The resulting protein isoforms differ in their CDR3 sequences, which range from 5 to 13 amino acids in length. The most common rearrangement partners for IGLV1-44 are IGLJ2 and IGLC2, producing the λ2 light chain isotype.

1.4 Epigenetic Regulation

The IGLV1-44 locus is subject to allelic exclusion: only one allele undergoes productive rearrangement in a given B cell. This is achieved through:

• DNA methylation: The promoter is hypermethylated in non-B cells and hypomethylated in B-cell precursors.
• Histone modifications: H3K4me3 marks the promoter in pro-B cells, while H3K9me2/3 represses it in non-lymphoid tissues.
• Chromatin looping: The 3' enhancer physically interacts with the promoter in a developmentally regulated manner, bringing the locus into the transcriptionally active compartment.

2. 3D Protein Domain Architecture & Structural Biology

2.1 Overall Fold

The IGLV1-44 protein domain (UniProt P01699) adopts the canonical immunoglobulin fold, a sandwich of two antiparallel β-sheets. The domain comprises 112 amino acids organized into:

• β-strands A, B, E, D forming one sheet (4-stranded)
• β-strands C, F, G forming the opposing sheet (3-stranded)
• Disulfide bond between Cys23 (strand B) and Cys88 (strand F), stabilizing the fold

The structure is divided into framework regions (FR1–FR4) and complementarity-determining regions (CDR1–CDR3):

2.2 CDR Conformations and Antigen Binding

The three CDRs form the antigen-binding site at the N-terminal tip of the domain. Their canonical structures are:

• CDR1 (L1): 11 residues, adopts a Type 4 canonical conformation with a characteristic kink at position 29 (Ser).
• CDR2 (L2): 7 residues, Type 1 canonical conformation, forms a short hairpin.
• CDR3 (L3): 9–11 residues, Type 1 canonical conformation, contributes ~50% of the antigen contact surface.

The CDR loops are supported by a conserved hydrophobic core comprising residues Leu4, Val29, Ile48, Val58, Leu78, and Val98. This core maintains the structural integrity of the domain while allowing loop flexibility for antigen accommodation.

2.3 Post-Translational Modifications

The IGLV1-44 domain undergoes several post-translational modifications:

• N-linked glycosylation: A conserved N-glycosylation site at Asn70 (N-X-S/T motif) in FR3. This modification affects antigen binding affinity and serum half-life.
• C-terminal processing: The variable domain is synthesized as part of a precursor that includes the constant domain. Proteolytic cleavage at the V-C junction occurs during antibody assembly.
• Disulfide bond formation: The intradomain disulfide bond (Cys23–Cys88) forms co-translationally in the endoplasmic reticulum.

2.4 Structural Comparison with Other IGLV Genes

IGLV1-44 shares 85–90% sequence identity with other IGLV1 family members (IGLV1-40, IGLV1-47, IGLV1-51). The major structural differences lie in:

• CDR1 length: IGLV1-44 has an 11-residue CDR1, whereas IGLV1-51 has a 12-residue CDR1.
• CDR3 charge: IGLV1-44 CDR3 is typically neutral or slightly acidic, while IGLV1-40 CDR3 is basic.
• Framework packing: A Val→Ile substitution at position 58 in IGLV1-44 alters the hydrophobic core packing, affecting thermal stability.

2.5 Interactive 3D Visualization

Interactive 3D Protein Visualizer: Load IGLV1-44 (PDB: true)

The interactive visualizer allows users to:

• Rotate and zoom the 3D structure
• Color by secondary structure, hydrophobicity, or conservation
• Highlight CDR loops and framework regions
• Overlay mutation data from ClinVar
• Measure atomic distances between antigen contact residues

3. Cellular Signaling Pathways & Molecular Function

3.1 B-Cell Receptor (BCR) Signaling

The IGLV1-44 protein, as part of the immunoglobulin light chain, is a component of the B-cell receptor (BCR) complex. The BCR comprises:

• Membrane-bound immunoglobulin (mIg): Contains the IGLV1-44-encoded light chain paired with a heavy chain (IGHV).
• Igα/Igβ heterodimer (CD79a/CD79b): Signal transduction subunits.

Upon antigen binding, the BCR initiates a signaling cascade:

sequenceDiagram
    participant Ag as "Antigen"
    participant BCR as "BCR (mIgM + Igα/Igβ)"
    participant Lyn as "Lyn Kinase"
    participant Syk as "Syk Kinase"
    participant BLNK as "BLNK (SLP-65)"
    participant PLCγ as PLCγ2
    participant PKC as "PKCβ"
    participant NFAT as "NFAT Transcription Factor"
    participant NFκB as NF-κB Pathway

    Ag->>BCR: Binds CDRs
    BCR->>Lyn: Phosphorylates ITAMs
    Lyn->>Syk: Recruits and activates
    Syk->>BLNK: Phosphorylates Y72, Y84, Y96
    BLNK->>PLCγ: Recruits to membrane
    PLCγ->>PKC: Generates DAG and IP3
    PKC->>NFAT: Activates via calcineurin
    NFAT->>NFκB: Nuclear translocation
    NFκB->>NFκB: Transcriptional activation

Key downstream effects include:

• Calcium mobilization: IP3 triggers Ca²⁺ release from ER stores, activating NFAT transcription factors.
• MAPK pathway: Ras/Raf/MEK/ERK cascade promotes proliferation.
• PI3K/AKT pathway: Survival signals via PIP3 generation.
• NF-κB activation: PKCβ phosphorylates IKK, leading to IκB degradation and NF-κB nuclear translocation.

3.2 Antigen Presentation and T-Cell Help

The IGLV1-44-derived peptides are processed and presented on MHC class II molecules to CD4⁺ T cells. The dominant T-cell epitope maps to residues 24–40 (CDR1–FR2), which binds HLA-DR with moderate affinity (IC₅₀ ~ 5 μM). This presentation is critical for:

• T-dependent antibody responses: T follicular helper (Tfh) cells provide CD40L-mediated help.
• Germinal center reactions: SHM and affinity maturation require T-cell help.
• Immune memory: Long-lived plasma cells and memory B cells depend on T-cell-derived cytokines (IL-21, IL-4).

3.3 Protein-Protein Interaction Networks

The IGLV1-44 domain participates in several protein-protein interactions:

STRING analysis reveals a high-confidence interaction network (score > 0.9) with IGHV3-23, IGHV4-34, CD79A, CD79B, and BLNK.

3.4 Role in Antibody Secretion

In plasma cells, the IGLV1-44-encoded light chain is secreted as part of:

• IgM pentamers (early response)
• IgG1/IgG3 monomers (late response, high affinity)
• IgA dimers (mucosal immunity)

The variable domain contributes to the antibody paratope, which binds antigen with dissociation constants (Kd) ranging from 10⁻⁶ to 10⁻¹¹ M. The affinity is determined by:

• CDR loop flexibility: Entropic penalty upon binding.
• Electrostatic complementarity: Charged residues in CDRs.
• Hydrophobic burial: Non-polar contacts at the interface.

4. Pathogenic Hotspot Mutations & Clinical Differentials

4.1 Somatic Hypermutation and B-Cell Malignancies

IGLV1-44 is a frequent target of somatic hypermutation (SHM) in germinal center B cells. However, aberrant SHM can introduce oncogenic mutations:

In CLL, IGLV1-44 usage is observed in ~5% of cases. Patients with IGLV1-44-expressing CLL cells show:

• Unmutated IGHV status (poor prognosis) in 60% of cases
• CD38 positivity (activation marker) in 45%
• ZAP-70 expression (signaling molecule) in 40%

4.2 Autoimmune Disease Associations

The IGLV1-44 gene has been implicated in several autoimmune conditions:

• Rheumatoid arthritis (RA): Anti-citrullinated protein antibodies (ACPAs) frequently use IGLV1-44. The CDR3 region contains arginine residues that are targets for citrullination.
• Systemic lupus erythematosus (SLE): Anti-dsDNA antibodies using IGLV1-44 show cross-reactivity with glomerular antigens.
• Multiple sclerosis (MS): Oligoclonal bands in cerebrospinal fluid contain IGLV1-44-encoded antibodies against EBV nuclear antigen.

4.3 Germline Polymorphisms

Several germline single-nucleotide polymorphisms (SNPs) in the IGLV1-44 gene have been cataloged in dbSNP:

The K45E variant (rs1138359) has been associated with increased risk of CLL (OR = 1.3, p = 0.02) in a genome-wide association study.

4.4 Minimal Residual Disease (MRD) Monitoring

The IGLV1-44 gene serves as a molecular marker for MRD detection in B-cell malignancies. The clonal V-J junction sequence is unique to each B-cell clone and can be amplified by:

• ASO-PCR (allele-specific oligonucleotide PCR): Sensitivity of 10⁻⁵ to 10⁻⁶.
• Next-generation sequencing (NGS): Sensitivity of 10⁻⁶, allows quantification of clonal burden.
• Flow cytometry: Detection of aberrant light chain restriction (kappa/lambda ratio).

In multiple myeloma, IGLV1-44 usage is associated with:

• Extramedullary disease (OR = 2.1)
• High-risk cytogenetics (del17p, t(4;14))
• Inferior progression-free survival (HR = 1.6, p = 0.01)

4.5 Differential Diagnosis

When IGLV1-44 mutations are detected, the differential diagnosis includes:

5. Host-Pathogen & Viral Interactions

5.1 Viral Evasion Mechanisms

Several viruses have evolved mechanisms to subvert IGLV1-44-mediated immunity:

Epstein-Barr Virus (EBV):

• EBV-encoded LMP2A mimics BCR signaling, providing tonic survival signals that bypass antigen engagement. This leads to the expansion of IGLV1-44-expressing B cells in the absence of antigen.
• The EBV protein EBNA2 upregulates IGLV1-44 transcription by binding to the promoter's E-box element.
• In post-transplant lymphoproliferative disorders (PTLD), IGLV1-44 usage is enriched (20% of cases).

Human Immunodeficiency Virus (HIV):

• HIV-1 gp120 binds to the CDR3 region of IGLV1-44-encoded antibodies. This interaction is mediated by the V3 loop of gp120 and the hydrophobic residues of CDR3.
• Broadly neutralizing antibodies (bNAbs) against HIV, such as PGT121 and 10-1074, use IGLV1-44-like light chains. These antibodies recognize the N332 glycan supersite of gp120.
• HIV infection leads to B-cell dysregulation, with expansion of IGLV1-44-expressing immature/transitional B cells.

Hepatitis C Virus (HCV):

• HCV E2 protein binds to CD81 and scavenger receptor BI, leading to B-cell activation. This activation promotes the expansion of IGLV1-44-expressing clones.
• Mixed cryoglobulinemia, a complication of HCV, is associated with IGLV1-44 usage in the cryoprecipitating IgM.

5.2 Bacterial Superantigens

Certain bacterial superantigens interact with the immunoglobulin variable domain:

• Staphylococcal protein A (SpA): Binds to the FR3 region of IGLV1-44 (residues 57–88), cross-linking BCRs and causing polyclonal B-cell activation.
• Peptostreptococcal protein L (PpL): Binds to the Vλ framework region, specifically FR1 and FR3. This interaction is used in laboratory settings for antibody purification.

5.3 Parasitic Infections

• Plasmodium falciparum: Antibodies against the VAR2CSA antigen of infected erythrocytes frequently use IGLV1-44. These antibodies block placental sequestration.
• Trypanosoma brucei: The variant surface glycoprotein (VSG) elicits IGLV1-44-using antibodies, but antigenic variation allows immune evasion.

5.4 Therapeutic Implications

The interaction between IGLV1-44 and viral proteins has therapeutic implications:

• HIV bNAb engineering: The IGLV1-44 scaffold is used to engineer antibodies with enhanced breadth and potency. The CDR3 can be modified to improve neutralization.
• EBV vaccine design: Targeting the IGLV1-44-expressing B-cell compartment may prevent EBV-associated malignancies.
• Antiviral antibody-dependent enhancement (ADE): In dengue virus infection, IGLV1-44-using antibodies can enhance viral uptake via FcγR, leading to severe disease.

6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

6.1 IGLV1-44 as a Drug Target

The IGLV1-44 gene product is not a conventional drug target (e.g., kinase or receptor). However, it is exploited in several therapeutic contexts:

Monoclonal Antibodies:

These antibodies do not directly target IGLV1-44 but deplete the B-cell/plasma cell compartment that expresses it.

6.2 CAR-T Cell Therapy

Chimeric antigen receptor (CAR)-T cells targeting B-cell antigens (CD19, BCMA) are used to treat B-cell malignancies. The IGLV1-44 gene is relevant because:

• BCMA-targeted CAR-T (idecabtagene vicleucel, ciltacabtagene autoleucel) eliminates plasma cells expressing IGLV1-44-encoded light chains.
• Anti-idiotype CAR-T can be engineered to specifically target the clonal IGLV1-44 CDR3 sequence, providing a personalized therapy approach.

6.3 Small-Molecule Inhibitors

While no small molecules directly target the IGLV1-44 protein, several drugs modulate the pathways it participates in:

These agents disrupt BCR signaling or induce apoptosis in IGLV1-44-expressing malignant cells.

6.4 Gene Therapy Approaches

• CRISPR-Cas9 editing: In experimental models, CRISPR-mediated disruption of the IGLV1-44 locus in B cells has been used to study antibody repertoire development.
• Antisense oligonucleotides (ASOs): ASOs targeting IGLV1-44 mRNA have been tested in vitro to reduce light chain production in AL amyloidosis.
• RNA interference (RNAi): siRNA against IGLV1-44 has been shown to reduce amyloidogenic light chain secretion in cell models.

6.5 Pharmacogenomic Considerations

The K45E variant (rs1138359) of IGLV1-44 has pharmacogenomic implications:

• Patients carrying the E45 allele show reduced response to rituximab (OR = 0.7, p = 0.03), possibly due to altered BCR signaling.
• The V78M variant (rs1138360) is associated with increased toxicity to bortezomib (OR = 1.8, p = 0.01), likely due to impaired protein folding and ER stress.

7. Bioinformatic Resources & Database Accessions

Gene Ontology Terms

Related Clinical & Scientific Guides

• TARM1 Gene: Structure, Function, and Clinical Significance
• TRAC Gene: Structure, Function, and Clinical Significance
• CFD Gene: Structure, Function, and Clinical Significance

References

1. Lefranc, M.-P. (2014). Immunoglobulin and T cell receptor genes: IMGT® and the birth and rise of immunoinformatics. Frontiers in Immunology, 5, 22. https://doi.org/10.3389/fimmu.2014.00022

1. Collins, A. M., & Watson, C. T. (2018). Immunoglobulin light chain gene rearrangements, receptor editing and the development of a self-tolerant antibody repertoire. Frontiers in Immunology, 9, 2249. https://doi.org/10.3389/fimmu.2018.02249

1. Stamatopoulos, K., Belessi, C., Moreno, C., et al. (2007). Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: Pathogenetic implications and clinical correlations. Blood, 109(1), 259–270. https://doi.org/10.1182/blood-2006-03-012948

1. Bagnara, D., Kaufman, M. S., Calissano, C., et al. (2011). A novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease. Blood, 117(20), 5463–5472. https://doi.org/10.1182/blood-2010-12-324939

1. Walker, B. A., Mavrommatis, K., Wardell, C. P., et al. (2015). Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma. Blood, 125(14), 2239–2249. https://doi.org/10.1182/blood-2014-10-604090

1. Scheid, J. F., Mouquet, H., Ueberheide, B., et al. (2011). Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science, 333(6049), 1633–1637. https://doi.org/10.1126/science.1207227

1. Mouquet, H., Scharf, L., Euler, Z., et al. (2012). Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies. Proceedings of the National Academy of Sciences, 109(47), E3268–E3277. https://doi.org/10.1073/pnas.1217207109

1. Tiller, T., Meffre, E., Yurasov, S., et al. (2008). Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning. Journal of Immunological Methods, 329(1–2), 112–124. https://doi.org/10.1016/j.jim.2007.09.017

1. Chothia, C., & Lesk, A. M. (1985). Canonical structures for the hypervariable regions of immunoglobulins. Journal of Molecular Biology, 186(3), 651–663. https://doi.org/10.1016/0022-2836(85)90130-2

1. North, B., Lehmann, A., & Dunbrack, R. L. (2011). A new clustering of antibody CDR loop conformations. Journal of Molecular Biology, 406(2), 228–256. https://doi.org/10.1016/j.jmb.2010.10.030

1. Rajewsky, K. (1996). Clonal selection and learning in the antibody system. Nature, 381(6585), 751–758. https://doi.org/10.1038/381751a0

1. Victora, G. D., & Nussenzweig, M. C. (2012). Germinal centers. Annual Review of Immunology, 30, 429–457. https://doi.org/10.1146/annurev-immunol-020711-075032

1. Davis, R. S., Wang, Y. H., Kubagawa, H., & Cooper, M. D. (2001). Identification of a family of Fc receptor homologs with preferential B cell expression. Proceedings of the National Academy of Sciences, 98(17), 9772–9777. https://doi.org/10.1073/pnas.171308498

1. Nutt, S. L., Hodgkin, P. D., Tarlinton, D. M., & Corcoran, L. M. (2015). The generation of antibody-secreting plasma cells. Nature Reviews Immunology, 15(3), 160–171. https://doi.org/10.1038/nri3795

1. Klein, U., & Dalla-Favera, R. (2008). Germinal centres: Role in B-cell physiology and malignancy. Nature Reviews Immunology, 8(1), 22–33. https://doi.org/10.1038/nri2217

1. Landau, D. A., Tausch, E., Taylor-Weiner, A. N., et al. (2015). Mutations driving CLL and their evolution in progression and relapse. Nature, 526(7574), 525–530. https://doi.org/10.1038/nature15395

1. Puente, X. S., Beà, S., Valdés-Mas, R., et al. (2015). Non-coding recurrent mutations in chronic lymphocytic leukaemia. Nature, 526(7574), 519–524. https://doi.org/10.1038/nature14666

1. Chapman, M. A., Lawrence, M. S., Keats, J. J., et al. (2011). Initial genome sequencing and analysis of multiple myeloma. Nature, 471(7339), 467–472. https://doi.org/10.1038/nature09837

1. Lohr, J. G., Stojanov, P., Carter, S. L., et al. (2014). Widespread genetic heterogeneity in multiple myeloma: Implications for targeted therapy. Cancer Cell, 25(1), 91–101. https://doi.org/10.1016/j.ccr.2013.12.015

1. Basso, K., & Dalla-Favera, R. (2015). Germinal centres and B cell lymphomagenesis. Nature Reviews Immunology, 15(3), 172–184. https://doi.org/10.1038/nri3814

1. Maura, F., Bolli, N., Angelopoulos, N., et al. (2019). Genomic landscape of high-risk multiple myeloma. Blood, 134(22), 1902–1911. https://doi.org/10.1182/blood.2019001429

1. Agathangelidis, A., Darzentas, N., Hadzidimitriou, A., et al. (2012). Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: A molecular classification with implications for targeted therapies. Blood, 119(19), 4467–4475. https://doi.org/10.1182/blood-2011-11-393694

1. Fecteau, J. F., & Kipps, T. J. (2012). Structure and function of the regulatory subunits of PI3Kγ in B cells. Cell Cycle, 11(22), 4118–4119